Pathological Features and Prognostication in Colorectal Cancer

Area of Science:

• Oncology
• Pathology
• Molecular Biology

Background:

• Colorectal cancer (CRC) prognostication traditionally relies on TNM staging (Union for International Cancer Control/American Joint Committee on Cancer).
• Observed survival variations independent of stage suggest other factors influence patient outcomes.
• Accurate prognostication is crucial for risk stratification and guiding neoadjuvant and adjuvant therapies.

Purpose of the Study:

• To comprehensively review pathological features and biomarkers critical for CRC prognostication.
• To explore how these factors aid in optimizing treatment strategies for colorectal cancer patients.
• To synthesize current evidence on the role of specific histological and molecular markers in CRC management.

Main Methods:

• Literature review synthesizing current evidence on prognostic factors in colorectal cancer.
• Analysis of established and emerging pathological features (e.g., tumor budding, lymph node yield).
• Evaluation of key molecular biomarkers (e.g., MSI, KRAS, BRAF, CDX2) in CRC prognostication.

Main Results:

• Histological features like tumor budding and perineural invasion are significant prognostic indicators.
• Molecular markers including microsatellite instability (MSI), KRAS, BRAF, and CDX2 mutations provide crucial prognostic information.
• These factors, alongside traditional staging, offer a more refined approach to risk stratification.

Conclusions:

• Pathological features and molecular biomarkers are essential for accurate colorectal cancer prognostication.
• Integrating these markers with staging improves risk assessment and treatment personalization.
• Further research into these factors will enhance therapeutic strategies and patient outcomes in CRC.